HIV, Lenacapavir and Gilead

GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir. Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention. Lenacapavir was granted breakthrough therapy designation for HIV prevention by the FDA in October 2024 and will be reviewed by the FDA under priority review,
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an intramuscular injection given as two once-yearly formulations for pre-exposure prophylaxis (PrEP) in HIV prevention.
Medscape25d
Optimizing Background Therapy in Treatment-Experienced HIV-1 Patients by Rules-Based Algorithms and Bioinformatics
In HIV-1-infected patients with extensive drug resistance, the optimization of background antiretroviral therapy is essential when changing drugs after treatment failure. The genotypic sensitivity ...
Rolling Out4d
Dr. Maya Green reveals 3 HIV prevention strategies
Dr. Maya Green discusses HIV prevention, addressing racial disparities in healthcare, and the powerful impact of stigma on ...